 We know that dexametazone is a backbone of multiple myeloma therapy because this is part of almost every myeloma regimen. And dexametazone has especially the highest dose of some strong immunosuppressive effect. And during the COVID-19 pandemic, I think the recommendation in multiple myeloma patients was about reducing the dose of dexametazone or even discontinue and stop dexametazone in some patients. Now we have heard we've seen recently some interesting results suggesting that low doses of dexametazone may be useful for treatment of the COVID-19 infection. I think we need to be careful and do not confuse or mix up things. Low dose dexametazone for treating COVID-19, we're talking about healthy patient, non myeloma patient. So totally different story to the myeloma patient who usually have a very long history, are highly immunocompromised. So for me, it's clearly important that we need to avoid any confusion between these two parameters. We're not using the same dosage. We're not using it for the same duration. We're not using dexametazone in the same context. So these are totally two different stories and multiple myeloma patient should be extremely careful and really follow the recommendations and prescriptions of their physicians.